Covalent Group, Inc. Schedules Fourth Quarter Financial Results and Conference Call
March 16 2006 - 7:57AM
Business Wire
Covalent Group, Inc. (Nasdaq: CVGR) ("Covalent"), a leader in the
design and management of complex clinical trials and patient
disease registries for the pharmaceutical, biotechnology and
medical device industries, today announced that it will issue its
financial results for the fourth quarter and year ended December
31, 2005 on March 21, 2006 after market close, with an accompanying
conference call on Wednesday, March 22, 2006 at 9:00 A.M. ET. To
participate in the live call by telephone, please dial (866)
550-5902, or for international callers, please dial (706) 643-2029.
Those interested in listening to the conference call live via the
Internet may do so by visiting the Company's Web site at
www.covalentgroup.com. Please go to the Web site 15 minutes prior
to the scheduled start to register, download, and install any
necessary audio software. A webcast audio replay will be available
through April 15, 2006. A telephone audio replay will also be
available through March 29, 2006, by dialing (800) 642-1687 from
the U.S., or (706) 645-9291 for international callers, and entering
conference ID number 6615207 when prompted. About Covalent Group,
Inc. Covalent Group, Inc. is a clinical research organization that
is a leader in the design and management of complex clinical trials
and Patient Disease Registries for the pharmaceutical,
biotechnology and medical device industries. The Company's mission
is to provide its clients with high quality, full-service support
for their biopharmaceutical development programs. Covalent offers
therapeutic expertise, experienced team management and advanced
technologies. The Company has drug and biologics development as
well as clinical trial experience across a wide variety of
therapeutic areas such as cardiovascular, endocrinology/metabolism,
diabetes, vaccines, infectious diseases, gene therapy, immunology,
neurology, oncology, gastroenterology, dermatology, hepatology,
women's health and respiratory medicine. Covalent believes that its
leadership in the design of complex clinical trials, its
therapeutic expertise and commitment to excellence, and its
application of innovative technologies, offer its clients a means
to more quickly and cost effectively move products through the
clinical development process. With its wholly-owned international
subsidiary, Covalent Group, Ltd., Covalent is able to meet the
North American and Western European drug development needs of its
clients. For more information, please visit www.covalentgroup.com.
This press release contains forward-looking statements identified
by words such as "estimate," "project," "expect," "intend,"
"believe," "anticipate" and similar expressions. Actual results
might differ materially from those projected in, expressed in or
implied by the forward-looking statements. Potential risks and
uncertainties that could affect the Company's future operating
results and financial condition include, without limitation: (i)
our success in attracting new business and retaining existing
clients and projects; (ii) the size, duration, and timing of
clinical trials we are currently managing may change unexpectedly;
(iii) the termination, delay or cancellation of clinical trials we
are currently managing could cause revenues to decline
unexpectedly; (iv) the timing difference between our receipt of
contract milestone or scheduled payments and our incurring costs to
manage these trials; (v) outsourcing trends in the pharmaceutical,
biotechnology and medical device industries; (vi) the ability to
maintain profit margins in a competitive marketplace; (vii) our
ability to attract and retain qualified personnel; (viii) the
sensitivity of our business to general economic conditions; (ix)
other economic, competitive, governmental and technological factors
affecting our operations, markets, products, services and prices;
(x) announced awards received from existing and potential customers
are not definitive until fully negotiated contracts are executed by
the parties;(xi) our backlog may not be indicative of future
revenues and may not generate the revenues expected;(xii) our
ability to successfully integrate the businesses of Covalent and
Remedium and (xiii) the performance of the combined business to
operate successfully and generate growth. You should not place any
undue reliance on these forward looking statements which speak only
as of the date of this press release. Additional information
concerning factors that might affect our business or stock price
which could cause actual results to materially differ from those in
forward-looking statements is contained in Covalent Group's SEC
filings, including its Annual Report on Form 10-K for the year
ended December 31, 2004 and other periodic reports under the
Securities Exchange Act of 1934, as amended, copies of which are
available upon request from Covalent Group's investor relations
department or The Equity Group Inc.
Covalent (NASDAQ:CVGR)
Historical Stock Chart
From May 2024 to Jun 2024
Covalent (NASDAQ:CVGR)
Historical Stock Chart
From Jun 2023 to Jun 2024